Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
FMR LLC (Fidelity) and Abigail P. Johnson have filed Amendment No. 11 to Schedule 13G reporting a 10.3 % passive stake in 10x Genomics (TXG) as of 31 Jul 2025. The filing discloses beneficial ownership of 11,529,806 Class A shares, including 892,772 Class B shares that are convertible 1-for-1 into Class A. FMR holds sole voting power over 11,496,050 shares and sole dispositive power over the full position; no shared power is reported.
The position is held through multiple Fidelity subsidiaries—Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company and Strategic Advisers LLC. Assuming full conversion of all Class B shares company-wide, the ownership would represent 9.36 % of the outstanding Class A shares.
The certification confirms the shares were acquired in the ordinary course of business and not for the purpose of influencing control. Signatures were executed on 6 Aug 2025 under an existing power of attorney.
FMR LLC (Fidelity) and Abigail P. Johnson have filed Amendment No. 11 to Schedule 13G reporting a 10.3 % passive stake in 10x Genomics (TXG) as of 31 Jul 2025. The filing discloses beneficial ownership of 11,529,806 Class A shares, including 892,772 Class B shares that are convertible 1-for-1 into Class A. FMR holds sole voting power over 11,496,050 shares and sole dispositive power over the full position; no shared power is reported.
The position is held through multiple Fidelity subsidiaries—Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company and Strategic Advisers LLC. Assuming full conversion of all Class B shares company-wide, the ownership would represent 9.36 % of the outstanding Class A shares.
The certification confirms the shares were acquired in the ordinary course of business and not for the purpose of influencing control. Signatures were executed on 6 Aug 2025 under an existing power of attorney.
FMR LLC, together with Abigail P. Johnson, filed Amendment No. 10 to Schedule 13G disclosing an 8.8 % beneficial ownership stake in 10x Genomics (TXG) Class A common stock as of 30 Jun 2025.
The filing reports 9,839,175.62 shares under sole dispositive power and 9,806,070 shares under sole voting power; no shared voting or dispositive power exists. The position includes 892,772 Class B shares held by Fidelity-advised funds that are convertible 1-for-1 into Class A, explaining the fractional share total. Assuming full conversion of all Class B shares outstanding, the reporting persons would own 7.99 % of the resulting Class A float.
FMR LLC is classified as a parent holding company (HC); Johnson is reported in her individual (IN) capacity. The certification states that the stake is held in the ordinary course of business and not for the purpose of influencing control. Signature authority is executed by Richard Bourgelas under power of attorney dated 23 May 2023. No group status or other material exhibits beyond Exhibit 99 (inter-company agreement) are referenced.